Experienced in Neural Crest Tumor

Dr. Mihaela Druta

Hematology | Oncology
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
12902 Usf Magnolia Dr, 
Tampa, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Neural Crest Tumor
H Lee Moffitt Cancer Ctr And Res Inst Life Time Cancer Scrn Ctr Inc
12902 Usf Magnolia Dr, 
Tampa, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mihaela Druta is a Hematologist and an Oncologist in Tampa, Florida. Dr. Druta is rated as an Experienced provider by MediFind in the treatment of Neural Crest Tumor. Her top areas of expertise are Synovial Sarcoma, Liposarcoma, Adult Soft Tissue Sarcoma, Myxoid Liposarcoma, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 25 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

H LEE MOFFITT CANCER CTR AND RES INST LIFE TIME CANCER SCRN CTR INC
12902 Usf Magnolia Dr, Tampa, FL 33612

Additional Areas of Focus

Dr. Druta has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Biological
Study Phase: Phase 1
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological
Study Drug: CAB-AXL-ADC
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Phase I Trial of Lymphodepletion Plus Adoptive Cell Therapy With High-Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
A Phase I Trial of Lymphodepletion Plus Adoptive Cell Therapy With High-Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: August 21, 2025
Intervention Type: Drug
Study Drugs: TIL, Interleukin-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Drug, Procedure
Study Drugs: Nivolumab, Azacitidine
Study Phase: Phase 1
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drug: Talimogene Laherparepvec
Study Phase: Phase 2
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
Enrollment Status: Completed
Publish Date: January 15, 2025
Intervention Type: Biological
Study Drug: CAB-ROR2-ADC
Study Phase: Phase 1/Phase 2
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Genetic
Study Phase: Phase 2
A Pilot Study of NY-ESO-1c259T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma
A Pilot Study of NY-ESO-1c259T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma
Enrollment Status: Completed
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drugs: Letetresgene autoleucel, Cyclophosphamide, Fludarabine
Study Phase: Phase 2
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer
A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 30, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

25 Total Publications

Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 21, 2025
Similar Doctors
Patrick T. Hwu
Advanced in Neural Crest Tumor
Dr. Patrick T. Hwu
Oncology
Advanced in Neural Crest Tumor
Dr. Patrick T. Hwu
Oncology
12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-745-4673
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Hwu is an Oncologist in Tampa, Florida. Dr. Hwu is rated as an Advanced provider by MediFind in the treatment of Neural Crest Tumor. His top areas of expertise are Melanoma, Metastatic Brain Tumor, Uveal Melanoma, and Metastatic Uveal Melanoma. Dr. Hwu is currently accepting new patients.

Experienced in Neural Crest Tumor
Dr. Syed Zafar
Hematology | Oncology
Experienced in Neural Crest Tumor
Dr. Syed Zafar
Hematology | Oncology

Florida Cancer Specialists And Research Institute, LLC

1970 Golf St, 
Sarasota, FL 
 (50.8 miles away)
941-957-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Syed Zafar is a Hematologist and an Oncologist in Sarasota, Florida. Dr. Zafar is rated as a Distinguished provider by MediFind in the treatment of Neural Crest Tumor. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, and Familial Colorectal Cancer.

Experienced in Neural Crest Tumor
Dr. Kapisthalam S. Kumar
Oncology | Hematology
Experienced in Neural Crest Tumor
Dr. Kapisthalam S. Kumar
Oncology | Hematology

Florida Cancer Specialists And Research Institute, LLC

14100 Fivay Rd, Suite 380, 
Hudson, FL 
 (26.2 miles away)
727-862-9026
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kapisthalam Kumar is an Oncologist and a Hematologist in Hudson, Florida. Dr. Kumar is rated as an Advanced provider by MediFind in the treatment of Neural Crest Tumor. His top areas of expertise are Familial Colorectal Cancer, Severe Congenital Neutropenia, Gastroesophageal Junction Cancer, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Kumar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Druta's expertise for a condition
ConditionClose
View All 20 Distinguished Conditions
View All 9 Advanced Conditions
View All 56 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile